Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group

Leukemia Research

Volumn 35, Issue 8, 2011, Pages 1108-1110

  Sayar, Hamid ^a   Chan, Rebecca J ^b   Orschell, Christie M ^b   Chan, Edward M ^c   Yu, Zhangsheng ^b   Hood, Daniel ^b   Plett, Artur ^b   Yang, Zhenyun ^b   Hui, Chua Lin ^b   Nabinger, Sarah C ^b   Kohlbacher, Kristopher J ^b   West, Evan S ^b   Walter, Amanda ^b   Sampson, Carol ^b   Wu, Jingwei ^b   Cripe, Larry D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Azacitidine; MDS; Myelodysplastic syndromes

Indexed keywords

AZACITIDINE; CD34 ANTIGEN; CD36 ANTIGEN; CD71 ANTIGEN; ERYTHROPOIETIN RECEPTOR; PROTEIN BCL XL; RECOMBINANT ERYTHROPOIETIN; TRANSCRIPTION FACTOR GATA 1;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BCL-X PROTEIN; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 79960265161     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.02.025     Document Type: Article

References (8)

1. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
2. Yang Z., Kondo T., Voorhorst C.S., Nabinger S.C., Ndong L., Yin F., et al. Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants. Mol Cell Biol 2009, 29:4376-4393.
3. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
4. Lyons R.M., Cosgriff T.M., Modi S.S., Gersh R.H., Hainsworth J.D., Cohn A.L., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27:1850-1856.
5. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol 2006, 24:3895-3903.
6. Yue G., Hao S., Fadare O., Baker S., Pozdnyakova O., Galili N., et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res 2008, 32:553-558.
7. Parker J.E., Fishlock K.L., Mijovic A., Czepulkowski B., Pagliuca A., Mufti G.J. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998, 103:1075-1082.
8. Kuo Y.Y., Chang Z.F. GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription. Mol Cell Biol 2007, 27:4261-4272.